• All
  • Primary Antibodies
  • Conjugated Antibodies for IF
  • Conjugated Antibodies for FC
  • Secondary Antibodies
  • Antibody Labeling KitsNew
  • ELISA Kits
  • IHC Kits
  • Magnetic Cell Separation Kits
  • Cytokines & Growth Factors
  • Neutralizing/activating Antibodies
  • Nanobody-based Reagents
  • Accessory Products and Kits
  • Fusion Proteins
×
×
Host
0
Species Reactivity
0
Species Reactivity
0
Conjugate
0
Conjugate
0
Compatible Species
0
Conjugate
0

DNAJB8 Rekombinanter Antikörper

DNAJB8 Rekombinant Antikörper für WB, Indirect ELISA

Wirt / Isotyp

Kaninchen / IgG

Getestete Reaktivität

human, Maus, Ratte

Anwendung

WB, Indirect ELISA

Konjugation

Unkonjugiert

CloneNo.

251752B7

Kat-Nr. : 86763-3-PBS

Synonyme

DJ6

Filter:
  • Western Blot (WB) analysis of various lysates using DNAJB8 Recombinant monoclonal antibody (86763-3-RR)

    WB analysis using 86763-3-RR (same clone as 86763-3-PBS)

    Various lysates were subjected to SDS PAGE followed by western blot with 86763-3-RR (DNAJB8 antibody) at dilution of 1:10000 incubated at room temperature for 1.5 hours. This data was developed using the same antibody clone with 86763-3-PBS in a different storage buffer formulation.

Geprüfte Anwendungen

Produktinformation

86763-3-PBS bindet in WB, Indirect ELISA DNAJB8 und zeigt Reaktivität mit human, Maus, Ratten

Getestete Reaktivität human, Maus, Ratte
Wirt / Isotyp Kaninchen / IgG
Klonalität Rekombinant
Typ Antikörper
Immunogen DNAJB8 fusion protein Ag10899
Vollständiger Name DnaJ (Hsp40) homolog, subfamily B, member 8
Berechnetes Molekulargewicht 232 aa, 26 kDa
Beobachtetes Molekulargewicht26 kDa
GenBank-ZugangsnummerBC029521
Gene symbol DNAJB8
Gene ID (NCBI) 165721
Konjugation Unkonjugiert
Form Liquid
Reinigungsmethode Protein-A-Reinigung
Lagerungspuffer PBS only
LagerungsbedingungenStore at -80°C. 20ul Größen enthalten 0,1% BSA.

Hintergrundinformationen

DNAJB8, a member of the DNAJ/HSP40 family of proteins, plays a crucial role in regulating chaperone HSP70 activity. It is known for its ability to suppress the aggregation of polyglutamine proteins through its C-terminal tail. Furthermore, DNAJB8 has been shown to inhibit TP53 through ubiquitin degradation in human colon cancer by directly interacting and upregulating MDR1, leading to increased oxaliplatin resistance. High levels of DNAJB8 in both colon tissues and serum are correlated with worse overall survival of colon cancer patients, suggesting that DNAJB8 level in serum sEV may serve as a potential biomarker for colon cancer and a promising therapeutic target for oxaliplatin-resistant cancer.